Vutrisiran · AMVUTTRA

RNA / oligonucleotide

Approvedregulatory verdict

Evidence outlook

Approved: Transthyretin Amyloidosis with Cardiomyopathy, Transthyretin Amyloidosis with Polyneuropathy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
EU
  • Cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM)investors.alnylam.com
  • Hereditary transthyretin-mediated amyloidosis (hATTR) in adults with stage 1 or stage 2 polyneuropathyEMA
Product first approved 2022
JP
  • TTR type familial amyloidosis with polyneuropathy
investors.alnylam.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (3)
Transthyretin Amyloidosis with Cardiomyopathy
NCT06679946 · Alnylam Pharmaceuticals
2024-12-03 – 2028-03-31 · Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
What this study did
Other / comorbidity
Phase 1 (1)
Other / comorbidity
NCT02797847 · Alnylam Pharmaceuticals
2016-06-07 – 2018-01-12 · Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Transthyretin Amyloidosis with Polyneuropathy
NCT07223203 · Alnylam Pharmaceuticals
2026-02-03 – 2031-06-12 · Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN
What this study did

Competitive landscape

This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Transthyretin Amyloidosis with Cardiomyopathy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Vutrisiran (AMVUTTRA): this drugApprovedRNA / oligonucleotideTransthyretin (TTR)Reliable signal
NCT04153149: Composite of all-cause mortality and recurrent cardiovascular events: overall population HR 0.718 (95% CI 0.555 to 0.929), p=0.0118; vutrisiran monotherapy subgroup HR 0.672 (95% CI 0.487 to 0.929), p=0.0162
Acoramidis (Attruby)ApprovedSmall moleculeTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication
CliramitugPhase 3Monoclonal antibodyTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication
Coramitug
Phase 3(overall)
Monoclonal antibodyTransthyretin (TTR)
not yet graded(overall)
No reviewed efficacy summary in this indication
Eplontersen (Wainua)Phase 3RNA / oligonucleotideTransthyretin (TTR)Partial signal
NCT04136171: CARDIO-TTRansform primary composite: rate ratio 0.89 (95% CI 0.73 to 1.09), P=0.28; no significant reduction. missed
Nexiguran ZiclumeranPhase 3Gene therapy / editingTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication
NucresiranPhase 3RNA / oligonucleotideTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow AMVUTTRA (Vutrisiran) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
March 2028 (1)
Phase 3Transthyretin Amyloidosis with CardiomyopathyEnrolling by invitation
Est. primary completion 2028-03-31 · NCT06679946 · CT.gov ↗
What to watch

See the full readout calendar ↗